{"id":116574,"date":"2026-08-17T18:54:08","date_gmt":"2026-08-17T18:54:08","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/116574\/"},"modified":"2026-08-17T18:54:08","modified_gmt":"2026-08-17T18:54:08","slug":"nestle-wants-to-turn-the-glp-1-threat-into-an-opportunity","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/116574\/","title":{"rendered":"Nestl\u00e9 Wants to Turn the GLP-1 Threat into an Opportunity"},"content":{"rendered":"

\"Nestl\u00e9<\/a> Nestl\u00e9 Wants to Turn the GLP-1 Threat into an Opportunity – Moby THE GIST <\/p>\n

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.<\/a> <\/p>\n

Nestl\u00e9 is turning the GLP-1 threat into an opportunity. The food giant known for Nesquik, Kit-Kat, and bottled water wants to use AI (because of course) to mine clinical research and design food products for the roughly 16 million Americans on GLP-1 weight-loss drugs. <\/p>\n

Don’t want Smarties? Fine, Nestle will push Vital Proteins then. <\/p>\n

WHAT HAPPENED <\/p>\n

Nestl\u00e9 is doubling down on its GLP-1 friendly product portfolio, as an increasing number of Americans are ditching most packaged foods. The company said it’s using AI and nutritional science to identify nutrient combinations, and build products tailored to Ozempic ilk. <\/p>\n

It’ll focus on products that address the side effects of GLP-1 drugs like Ozempic, including drastic changes in facial fat and muscle loss. For instance, Nestle added collagen protein to its Vital Proteins brand to target skin, hair and nail concerns tied to rapid weight loss. The company has also patented proprietary ingredient combinations meant to curb the rebound hunger many people experience after stopping GLP-1 treatment. <\/p>\n

What does that look like on the supermarket aisles? Boost Advanced Nutrition Shake with 35 grams of protein to support muscle health during weight loss, and the Vital Pursuit line of high-protein, portion-aligned frozen meals. <\/p>\n

WHY IT MATTERS <\/p>\n

It’s a no brainer that Nestle is chasing this market. <\/p>\n

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.<\/a> <\/p>\n

The Boston Consulting Group estimates roughly 16 million Americans currently take GLP-1 medicines, a figure expected to climb sharply by the end of the decade; A separate J.P. Morgan Research projected US GLP-1 users could reach 30 million, or about 9% of the population, by 2030. So, yeah, not many will be taking a break with KitKat. <\/p>\n

Instead of fighting the tide, Nestle’s trying to swim with it. It’s betting that the same drugs also create a parallel need: products addressing the physical side effects of fast weight loss, sold to a captive and expanding customer base. <\/p>\n

It’s hard to beat whole foods like eggs, beans, nuts and pulses on nutrition and budget, but that’s why we have marketing. Nestle’s relying on its marketing expertise to suggest products branded specifically for GLP-1 users will likely find buyers regardless of nutritional necessity. <\/p>\n

WHAT’S NEXT <\/p>\n

Nestl\u00e9 isn’t relying only on its own in-house R&D. It engaged academics at UC Davis, to accelerate innovation in weight management, women’s health and longevity, while signaling that more GLP-1-focused products are on the way. <\/p>\n

The bigger test will be commercial: whether Nestl\u00e9’s product pipeline can outpace the drugs’ impact on demand for packaged foods, and whether its nutrition-science credibility can outpace its targeted marketing. <\/p>\n

Until then, it’s an apple a day. <\/p>\n","protected":false},"excerpt":{"rendered":"Nestl\u00e9 Wants to Turn the GLP-1 Threat into an Opportunity – Moby THE GIST Our analysts just identified…\n","protected":false},"author":2,"featured_media":116575,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[126],"tags":[1102,22559,199,56745,56744,1904],"class_list":["post-116574","post","type-post","status-publish","format-standard","has-post-thumbnail","category-nestle","tag-clinical-research","tag-food-products","tag-nestle","tag-nutritional-science","tag-vital-proteins","tag-weight-loss"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117112370916195345","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/116574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=116574"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/116574\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/116575"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=116574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=116574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=116574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}